You can read the IBTA e-News July 2018 edition in full online here.
Some of the highlights from this month's monthly round-up:
- We are delighted to announce that the recently formed Society for Neuro-Oncology Sub-Saharan Africa (SNOSSA) held their first conference, entitled "A New Dawn for NeuroOncology in Sub-Saharan Africa", on 22nd - 23rd July, 2018 in Abuja, Nigeria. SNOSSA arose out of the Sub-Saharan Africa Neuro-Oncology Collaborative (S-SANOC) Planning Meeting (see below) organised by the IBTA in conjunction with the Society for Neuro-Oncology (SNO) and the Zimbabwe Brain Tumour Association (ZBTA).
- It has been announced that eligible brain tumour patients in all of England’s neurosurgical units are to receive 5-aminolevulinic acid (5-ALA) – a tumour-enhancing fluorescent dye administered before surgery to maximise resection – according to new national NICE guidance
- Australian Prime Minister Malcolm Turnbull and Federal Health Minister Greg Hunt have announced AUD $5million in funding from the Medical Research Future Fund for the Zero Childhood Cancer brain cancer program
- Research published in Nature Medicine has identified how mutations in the IDH1 gene in glioma cells impair the immune system’s ability to attack it. Even though the immune system is capable of identifying and fighting tumours with the IDH1 gene, this study found that a product of the mutation, called 2-HG, directly impaired cells of the immune system.
- A drug used to treat altitude sickness - as well as glaucoma, epilepsy, heart failure and seizures – called acetazolamide may have the potential to improve temozolomide chemotherapy in glioblastoma, according to animal-based research published in the journal Science Translational Medicine.
- Research published in Nature Cell Biology has indicated that the protein AMPK (AMP-activated protein kinase) may be a key driver of glioblastoma growth, contrary to previous research which has suggested it as a suppressor of tumour growth.
- Phase 1 trial results of an immunotherapy called G207, which is derived from the herpes virus responsible for cold sores (HSV-1), showed no anti-tumour effects in five of the six patients, with an ongoing response in one patient 18 months after treatment.
- Results from a phase 1 clinical trial suggest that a convection-enhanced delivery system (dubbed “chemosurgery”) is a viable future treatment in childhood/young adult diffuse intrinsic pontine glioma (DIPG), according to data published in The Lancet Oncology.
- A Diffuse Intrinsic Pontine Glioma (DIPG) tissue donation ‘portal’ has been opened at the Translational Genomics Research Institute (TGen) in Arizona, USA, for the creation of a brain tumour tissue bank that will accelerate research.
- An All.Can patient survey designed to gain insights on inefficiencies in cancer care has now been launched in Australia. Patients and caregivers can share thoughts and experiences on where inefficiencies occur in their healthcare pathways and how cancer care could be improved.
- An international multi-disciplinary consortium, comprised of four partners from three EU Member States, is embarking on a project called GLIOMA-PRD, which aims to use computer modelling to integrate molecular, genetic, imaging, and other brain tumour data for predicting the clinical evolution of glioma in individual patients.
- In work published in Cell Reports, researchers have shown that a gene fusion, caused by a chromosomal event called chromothripsis, is sufficient to trigger ependymoma tumour formation in otherwise normal brain cells.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.